DNA Binding Drugs Targeting the Regulatory DNA Binding Site of the ETS Domain Family Transcription Factor Associated With Human Breast Cancer
Abstract
The goal of this project is to test and to develop a new class of drugs, polyamide, which can selectively and effectively inhibit the function of transcription factors whose aberrant regulation of gene expression is associated with human breast cancer. The Her2/neu oncogene promoter is selected as a model for this study. The key approach is to prevent the binding of two transcription factors, ESX and AP-2, to the consensus DNA binding sites contained within the Her2/neu promoter resulting in inhibition of transcription factor function. If successful, the drugs will be able to prevent the targeted transcription factors from binding to DNA and thus they cannot enhance the activity of the proteins associated with the cancer cell. These new types of drugs have potential to be designed specifically to block the cellular proteins that are implicated in human breast cancers. Not only will these drugs have the potential to become a new type of anticancer agent they may also be used as tools to identify other proteins involved in breast cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 1999
- Accession Number
- ADA381309
Entities
People
- Yong-dong Wang
Organizations
- Health Research, Incorporated